Comparative Pharmacology
Head-to-head clinical analysis: ABILIFY versus ABILIFY MAINTENA KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABILIFY versus ABILIFY MAINTENA KIT.
ABILIFY vs ABILIFY MAINTENA KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
400 mg IM once monthly after establishing tolerability with oral aripiprazole.
None Documented
None Documented
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Aripiprazole: 75-146 hours; dehydro-aripiprazole: 94-146 hours. Long half-life allows monthly intramuscular dosing.
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
Renal (approximately 25% unchanged and 55% as metabolites); fecal (approximately 20% as metabolites).
Category C
Category C
Atypical antipsychotic
Atypical antipsychotic